Medicare adds 15 drugs, including Botox and Trulicity, to price negotiations.

The Trump administration announced a new round of Medicare drug price negotiations that, for the first time, includes office-administered drugs covered under Part B. Fifteen high-spending drugs were selected and negotiated prices are scheduled to take effect in 2028.

The administration has launched another round of Medicare drug price negotiations and expanded the program to include treatments given in doctors' offices. Previously, talks covered only retail drugs under Medicare Part D. Officials released a group of 15 highest-spending drugs now subject to negotiations. The negotiated prices are set to take effect in 2028. What is known: - The 2026 selection includes drugs covered by Medicare Part B, marking the first time office-administered treatments are in the talks. - Fifteen drugs were named, including Botox and Botox Cosmetic, Eli Lilly’s Trulicity, and Gilead’s Biktarvy; the administration also released a broader list of 50 negotiation-eligible drugs. - About 1.8 million beneficiaries used the selected medications between November 2024 and October 2025, and those drugs accounted for roughly $27 billion in Medicare Part B and D spending, according to the Centers for Medicare and Medicaid Services. - Some analysts note that for most manufacturers Medicare revenue exposed to these negotiations represents a small share of their worldwide sales; one analyst estimated higher exposure only for Gilead’s Biktarvy. Summary: Negotiated prices for the 15 selected drugs are scheduled to apply in 2028 and are intended to lower costs for beneficiaries. Negotiations will proceed under the program framework announced by officials, and the administration has released the full list of eligible drugs for this round.